At the American Society of Clinical Oncology Genitourinary Cancer Symposium, Judd W. Moul, MD, a urologist at Duke Cancer Institute, details his real-world research involving African American patients and those with high BMI and their response to androgen deprivation therapy.
Dr. Moul on Mortality Risk After ADT in African American Patients With Prostate Cancer
By Judd W. Moul, MD - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.